In parallel with the CSF results, when using the more precise SIMOA technology to measure total tau levels in plasma samples, the linear regression model adjusted for age and sex revealed significantly higher levels in the healthy control group (control: 7.51 ± 0.73 pg/mL) compared to plasma samples of non-treated adult SMA patients (SMA(Pre): 2.98 ± 0.37 pg/mL) [F(1,54) = 11.463, p = 0.001]. The gene discussed is MAPT; the disease is proximal spinal muscular atrophy.